相似文献
1
Pharmacotherapy for uveitis: current management and emerging therapy.
Clin Ophthalmol. 2014 Sep 22;8:1891-911. doi: 10.2147/OPTH.S47778. eCollection 2014.
2
Systemic immunosuppressive therapies for uveitis in developing countries.
Indian J Ophthalmol. 2020 Sep;68(9):1852-1862. doi: 10.4103/ijo.IJO_1548_20.
3
Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials.
Expert Opin Emerg Drugs. 2023 Dec;28(4):297-309. doi: 10.1080/14728214.2023.2293049. Epub 2023 Dec 26.
4
Recommendation of using systemic anti-tumor necrosis factor-alpha for the treatment of noninfectious uveitis in Taiwan.
Taiwan J Ophthalmol. 2018 Jul-Sep;8(3):117-120. doi: 10.4103/tjo.tjo_32_18.
5
Side-effects of anti-inflammatory therapy in uveitis.
Semin Ophthalmol. 2014 Sep-Nov;29(5-6):456-67. doi: 10.3109/08820538.2014.959203.
6
Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.
Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7462-6. doi: 10.1073/pnas.96.13.7462.
7
Autoimmune uveitis: clinical, pathogenetic, and therapeutic features.
Clin Exp Med. 2016 May;16(2):125-36. doi: 10.1007/s10238-015-0345-6. Epub 2015 Mar 28.
8
Intravitreal injection therapy in the treatment of noninfectious uveitis.
Dev Ophthalmol. 2012;51:110-21. doi: 10.1159/000336471. Epub 2012 Apr 17.
9
New pharmacotherapy options for noninfectious posterior uveitis.
Expert Opin Biol Ther. 2014 Dec;14(12):1783-99. doi: 10.1517/14712598.2014.956074. Epub 2014 Sep 22.
10
A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I.
Expert Opin Pharmacother. 2014 Oct;15(15):2141-54. doi: 10.1517/14656566.2014.948417.
引用本文的文献
1
Efficacy and tolerability of subcutaneous repository corticotropin injection in refractory ocular inflammatory diseases.
J Ophthalmic Inflamm Infect. 2024 Oct 24;14(1):56. doi: 10.1186/s12348-024-00428-8.
2
Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond.
Front Ophthalmol (Lausanne). 2024 Aug 2;4:1412930. doi: 10.3389/fopht.2024.1412930. eCollection 2024.
3
Healthcare professionals' views on the most important outcomes for non-infectious uveitis of the posterior segment: A qualitative study.
PLoS One. 2023 Nov 17;18(11):e0294117. doi: 10.1371/journal.pone.0294117. eCollection 2023.
4
Effects of Subcutaneous Methotrexate in Patients with Refractory Uveitis and Chorioretinitis.
Korean J Ophthalmol. 2023 Dec;37(6):446-452. doi: 10.3341/kjo.2023.0073. Epub 2023 Oct 25.
5
Extracellular vesicles as a new horizon in the diagnosis and treatment of inflammatory eye diseases: A narrative review of the literature.
Front Immunol. 2023 Mar 9;14:1097456. doi: 10.3389/fimmu.2023.1097456. eCollection 2023.
6
Comprehensive LncRNA and Potential Molecular Mechanism Analysis in Noninfectious Uveitis.
Transl Vis Sci Technol. 2023 Mar 1;12(3):2. doi: 10.1167/tvst.12.3.2.
7
Topical Anti-Inflammatory Agents for Non-Infectious Uveitis: Current Treatment and Perspectives.
J Inflamm Res. 2022 Nov 28;15:6439-6451. doi: 10.2147/JIR.S288294. eCollection 2022.
8
Practice patterns regarding regional corticosteroid treatment in noninfectious Uveitis: a survey study.
J Ophthalmic Inflamm Infect. 2022 Jan 4;12(1):3. doi: 10.1186/s12348-021-00281-z.
9
Annexin A1 Mimetic Peptide and Piperlongumine: Anti-Inflammatory Profiles in Endotoxin-Induced Uveitis.
Cells. 2021 Nov 15;10(11):3170. doi: 10.3390/cells10113170.
10
A Non-Infectious Uveitis Multidisciplinary Clinic in a Tertiary Referral Center: Clinical Impact and Added Value.
J Multidiscip Healthc. 2021 Mar 22;14:695-704. doi: 10.2147/JMDH.S292981. eCollection 2021.
本文引用的文献
1
Update on the use of systemic biologic agents in the treatment of noninfectious uveitis.
Biologics. 2014 Feb 15;8:67-81. doi: 10.2147/BTT.S41477. eCollection 2014.
2
Acute anterior uveitis after discontinuation of tocilizumab in a patient with rheumatoid arthritis.
Clin Ophthalmol. 2014 Jan 8;8:187-90. doi: 10.2147/OPTH.S54929. eCollection 2014.
3
Interleukin-6 blockade in ocular inflammatory diseases.
Clin Exp Immunol. 2014 Jun;176(3):301-9. doi: 10.1111/cei.12295.
4
Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient.
Ocul Immunol Inflamm. 2014 Apr;22(2):155-7. doi: 10.3109/09273948.2013.866254. Epub 2013 Dec 30.
5
New options for uveitis treatment.
Int J Ophthalmol. 2013 Oct 18;6(5):702-7. doi: 10.3980/j.issn.2222-3959.2013.05.29.
6
Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties.
J Pharmacol Exp Ther. 2014 Jan;348(1):202-15. doi: 10.1124/jpet.113.205443. Epub 2013 Nov 5.
7
The future of uveitis treatment.
Ophthalmology. 2014 Jan;121(1):365-376. doi: 10.1016/j.ophtha.2013.08.029. Epub 2013 Oct 26.
8
Long-term treatment with golimumab for severe uveitis.
Ocul Immunol Inflamm. 2014 Apr;22(2):90-5. doi: 10.3109/09273948.2013.844265. Epub 2013 Oct 21.
9
Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series.
Clin Exp Ophthalmol. 2014 May-Jun;42(4):392-5. doi: 10.1111/ceo.12207. Epub 2013 Oct 23.
10
Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.
Mediators Inflamm. 2013;2013:286857. doi: 10.1155/2013/286857. Epub 2013 Aug 1.
Zotero 插件